

# Filamin B extensively regulates transcription and alternative splicing, and is associated with apoptosis in HeLa cells

HAI-RONG MA<sup>1\*</sup>, LI CAO<sup>2\*</sup>, FEI WANG<sup>2</sup>, CHAO CHENG<sup>3</sup>, RENDONG JIANG<sup>2</sup>,  
HAIKANG ZHOU<sup>2</sup>, ZHENZI XIE<sup>4</sup>, SHALITANATI WUERMANBIEKE<sup>2</sup> and ZHENGHAO QIAN<sup>2</sup>

<sup>1</sup>State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medicine Institute, The First Affiliated Hospital of Xinjiang Medical University; <sup>2</sup>Department of Orthopaedics, The First Affiliated Hospital of Xinjiang Medical University, Urumqi, Xinjiang 830054; <sup>3</sup>ABLIFE BioBigData Institute, Wuhan, Hubei 430075; <sup>4</sup>College of Life Sciences, HaiNan Normal University, Haikou, Hainan 571158, P.R. China

Received August 7, 2019; Accepted January 14, 2020

DOI: 10.3892/or.2020.7532

**Abstract.** Post-transcriptional mechanisms are an important approach in the treatment of cancer, and may also be hijacked by tumor cells to help adapt to the local microenvironment. Filamin B (*FLNB*), an actin-binding protein that provides crucial scaffolds for cell motility and signaling, has also been identified as an RNA-binding protein. Recent studies demonstrated that *FLNB* might play an important role, not only in skeletal development, but also in regulating tumorigenesis; however, the effects of dysregulated expression of *FLNB* at the molecular level are not clear. In the present study, RNA-sequencing was performed to analyze changes in overall transcriptional and alternative splicing between the knocked-down *FLNB* and the control in HeLa cells. Decreased *FLNB* levels resulted in significantly lower apoptosis compared with control cells. *FLNB* knockdown extensively regulated the expression of genes in cell apoptosis, tumorigenesis, metastases, transmembrane transport and cartilage development. Moreover, *FLNB* regulated alternative splicing of a large number of genes involved in ‘cell death’ and the ‘apoptotic process’. Some genes and alternative splicing related to skeletal development were enriched and regulated by *FLNB*. Reverse

transcription-quantitative-PCR identified *FLNB*-regulated transcription and alternative splicing of genes, such as NLR family apoptosis inhibitory protein, interleukin 23 subunit  $\alpha$ , metastasis associated lung adenocarcinoma transcript 1, phosphofurin acidic cluster sorting protein 2, bone morphogenetic protein 7, matrix metalloproteinase 13, collagen type II  $\alpha$  1 chain, fibroblast growth factor receptor 2 and vitamin D receptor. The present study is the first study, to the best of the authors’ knowledge, to provide transcriptome-wide analysis of differential gene expression and alternative splicing upon *FLNB* silencing. The present results suggested that *FLNB* may play an important regulatory role in cervical cancer cell apoptosis via regulation of transcription and alternative splicing, which provide insight for the current understanding of the mechanisms of *FLNB*-mediated gene regulation.

## Introduction

Filamin B (*FLNB*) is a member of the filamin family, which is a group of highly conserved actin-binding proteins that is responsible for anchoring the actin network to cellular membranes and transmembrane receptors. The *FLNB* gene was first isolated using a yeast two-hybrid system by Takafuta *et al* (1). The *FLNB* gene is located at chromosome 3p14.3 and encodes a protein of 2,602 amino acids (2). *FLNB*, as a cytoskeletal protein, is broadly distributed across the entire cell (more in the cytoplasm than in the nucleus) and expressed in different tissues, such as blood vessels, colon, breast, prostate and skeletal muscle (3,4). *FLNB* consists of an N-terminal actin-binding domain, followed by immunoglobulin-like repeat domains that form a receptor-binding region at the C-terminus (5). The *FLNB* structure facilitates execution of dual functions in two ways: Assisting to form a three-dimensional network of actin through the actin-binding domain; and acting as scaffolding proteins for receptor activation and signal transduction, then directing various cell functions, including membrane stability, ion channel transport, adhesion, proliferation, protrusion and motility (6). *FLNB* has been identified to play vital roles in skeletal disorders. It was previously identified that *FLNB* mutations or deficiencies cause multiple skeletal malformations, including scoliosis,

*Correspondence to:* Dr Hai-Rong Ma, State Key Laboratory of Pathogenesis, Prevention and Treatment of High Incidence Diseases in Central Asia, Clinical Medicine Institute, The First Affiliated Hospital of Xinjiang Medical University, 393 South LiYuShan Road, Urumqi, Xinjiang 830054, P.R. China  
E-mail: mhersj@163.com

Professor Li Cao, Department of Orthopaedics, The First Affiliated Hospital of Xinjiang Medical University, 393 South LiYuShan Road, Urumqi, Xinjiang 830054, P.R. China  
E-mail: xjbone@sina.com

\*Contributed equally

**Key words:** filamin B, *FLNB*, HeLa cell, apoptosis, alternative splicing, RNA binding, RNA-sequencing

spondylocarpotarsal synostosis, Larsen syndrome, atelosteogenesis, boomerang dysplasia, clubfoot, joint dislocation and other unique skeletal abnormalities (7,8).

It has been recently demonstrated that *FLNB* plays an important role in cancer. Several previous studies demonstrated that *FLNB* expression was highly correlated with tumor proliferation, metastasis and invasiveness. For example, Bandaru *et al* (9) identified that a *FLNB* gene deficiency in mouse embryonic fibroblasts increased the expression and proteolytic activity of matrix metalloproteinase-9 (MMP-9), as well as cell invasion mediated by the RAS/ERK pathway. Another previous *in vitro* study demonstrated that *FLNB* is highly expressed in several cancer cells, such as A549 (adenocarcinomic human alveolar basal epithelial cells) and HT1080 (fibrosarcoma cell line) cells, which exhibit high invasiveness (10). In particular, an alternative splicing (AS) switch in *FLNB* promotes the epithelial-to-mesenchymal transition (EMT) in human breast cancer (11).

Notably, Baltz *et al* (12) identified that *FLNB* functions as an RNA-binding protein (RBP) using a photoreactive nucleotide-enhanced UV cross-linking and oligo(dT) purification method. RBPs are involved in virtually all steps of this post-transcriptional regulation, including RNA splicing, polyadenylation, stability, localization, translation and degradation, and defects in RBPs have been linked to many human disorders, including cancer, immunologic disorders and neurodegenerative diseases (13-15). Therefore, it was hypothesized that *FLNB* has important regulatory functions in regulation of AS and transcription in cancer, which has not been previously reported, to the best of the authors' knowledge.

In the present study, *FLNB* was knocked down using short hairpin RNA (shRNA) in HeLa cells derived from human cervical cancer cells. It was demonstrated that cell apoptosis was significantly inhibited. Then, high-throughput RNA-sequencing (RNA-seq) was performed to comprehensively analyze the transcriptome changes of the knocked-down *FLNB* compared with controls. The present results identified that *FLNB* regulated the transcription and AS of subsets of genes, especially those involved in apoptosis, proliferation and chondrocyte development signaling pathways. The present results may provide insight for the current understanding of *FLNB* in regulating gene transcription and AS in cancer.

## Materials and methods

**Sample preparation and *FLNB* knockdown.** Human HeLa cells (CCTCC@GDC0009) were obtained from The China Center for Type Culture Collection. HeLa cells were cultured in DMEM (Gibco; Thermo Fisher Scientific, Inc.) with 100 µg/ml streptomycin, 10% FBS (Gibco; Thermo Fisher Scientific, Inc.), and 100 U/ml penicillin at 37°C in 5% CO<sub>2</sub>. Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) was used to perform plasmid transfection of HeLa, according to the manufacturer's protocol. In total, 2.5 µg plasmid was used to transfect ~5x10<sup>5</sup> HeLa cells in each well of a 6-well plate. The shRNA sequence for silencing *FLNB* was 5'-CCTTCAGGAATCGGATTA-3'. The primer was synthesized by Sangon Biotech Co., Ltd. HeLa cells which were transfected with empty vector were used as controls.

*FLNB* knockdown efficiency was assessed by reverse transcription-quantitative (RT-qPCR) by comparing sh*FLNB* groups and control groups with Student's t-test, and GAPDH was used as a control after 48 h of transfection. RNA was extracted using TRIzol® kit (Thermo Fisher Scientific, Inc.) and reverse transcribed into cDNA using M-MLV Reverse Transcriptase (Vazyme Biotech Co., Ltd.). The RT procedure included incubation at 37°C for 15 min and then 85°C for 5 sec. Real-time PCR was performed with the StepOne RealTime PCR system (Thermo Fisher Scientific, Inc.) using PrimeScript™ RT reagent kit (Takara Bio, Inc). The PCR conditions consisted of denaturing at 95°C for 10 min, 40 cycles of denaturing at 95°C for 15 sec, annealing and extension at 60°C for 30 sec. PCR amplifications were performed in triplicate for each sample that normalized with the reference gene GAPDH, and the data was assayed using the comparative Cq (2<sup>-ΔΔCq</sup>) method (16). Primers of *FLNB* and GAPDH for qPCR analysis are presented in Table S1.

**Cell proliferation and apoptosis assay.** Cell proliferation was assessed using an MTT assay. In total, 5x10<sup>3</sup> cell/well HeLa cells were cultured in 96-well plates. Then, cells were transfected with the vector using Lipofectamine® 2000 (Invitrogen; Thermo Fisher Scientific, Inc.) according to the manufacturer's protocol. After incubation at 37°C for 48 h, MTT solution (5 mg/ml; 0.025 ml) was added to each well. The cells were incubated for another 4 h and the supernatant was removed from each well. The colored formazan crystals produced by MTT were dissolved in DMSO (0.15 ml) and the optical density was measured at 490 nm.

For the flow cytometric analysis of cell apoptosis, the transfected cells were incubated at 37°C for 48 h, and the live cells were harvested and washed twice with ice-cold 1X PBS. Viable cells were double-stained with 7-amino actinomycin D and FITC-conjugated Annexin V (Beijing 4A Biotech Co., Ltd.). The percentage of cell apoptosis was calculated as the sum of the right lower and upper quadrants. The number of stained cells was quantified using a flow cytometer (CytoFLEX; Beckman Coulter, Inc.). Cell cycle distribution was quantified using multi-cycle software (FlowJo 10.5.3; FlowJo, LLC).

**Statistical analysis.** Student's t-test was used to assess differences between the *FLNB* knockdown and control groups. The results of each experiment are presented as the mean ± SD of three experiments. The data were analyzed using SPSS 19.0 software (IBM Corp.). P<0.05 was considered to indicate a statistically significant difference.

**RNA-seq library preparation and sequencing.** Total RNA was extracted using TRIzol® (Invitrogen; Thermo Fisher Scientific, Inc.) and then was purified with two phenol-chloroform treatments. The RNA-seq library was prepared with 1 µg total RNA for each sample using the VAHTS Stranded mRNA-seq Library Prep kit (Vazyme Biotech Co., Ltd.). The libraries were then applied to the Illumina HiSeq X Ten system (Illumina, Inc.) for 150 nt paired-end sequencing.

**RNA-Seq and differentially expressed gene (DEG) analysis.** Adaptors were removed from raw reads using cutadapt and low-quality bases were trimmed using FASTX-Toolkit

(version 0.0.13; [http://hannonlab.cshl.edu/fastx\\_toolkit/index.html](http://hannonlab.cshl.edu/fastx_toolkit/index.html)). Reads >16 nt were aligned to the human GRCh38 genome using Tophat2 (17). Uniquely mapped reads were used for counting gene reads. Fragments per kilobase of transcript per million fragments mapped (FPKM) (18) was calculated for the gene expression level. edgeR (19) and DESeq2 (20) was utilized to screen out the DEGs. A false discovery rate (FDR)<0.05 and log<sub>2</sub> fold change ≥1 or ≤-1 were set as the cut-off criteria for identifying DEGs. Pearson's correlation analysis was performed to assess sample distance.

**AS analysis.** The AS analysis was performed using the ABLas pipeline, as previously described (21,22). ABLas detects 10 types of alternative splicing events (ASEs) based on the splice junction reads and uniquely mapped reads. These ASEs include exon skipping (ES), alternative 3'splice site (A3SS), intron retention, alternative 5'splice site (A5SS), mutually exclusive exons (MXEs), mutually exclusive 3'untranslated regions (UTRs), mutually exclusive 5'UTRs, cassette exon, A3SS&ES and A5SS&ES.

To assess RBP-regulated ASEs, ABLas used Student's t-test to evaluate the significance of the ratio alteration of ASEs. Those events that were significant at the cut-off of FDR≤5% were considered RBP-regulated ASEs.

**Validation of DEGs and ASEs using RT-qPCR and western blotting.** RT-qPCR reactions were performed for validation of transcription levels and AS changes. The primer information is presented in Table SI. Total RNA remaining from the RNA-seq library preparation was used for RT-qPCR as previously described. The level of RNA expression for all genes was normalized against GAPDH. For ASEs validation, the primers for detecting ASEs are presented in Table SI. To detect alternative isoforms, a boundary-spanning primer of constitutive and alternative exons was used, as well as an opposing primer in one constitutive exon. The boundary-spanning primer of the alternative exon was designed according to a 'model exon' to detect model splicing, or an 'altered exon' to detect altered splicing.

Western blot analysis was performed for validation of protein expression. Radioimmunoprecipitation assay lysis buffer with protease inhibitors (Sigma-Aldrich; Merck KGaA) was used to lyse treated cells on ice for 30 min, according to the manufacturer's protocol. The protein concentration was determined by the bicinchoninic acid protein assay kit (Sangon Biotech Co., Ltd.). Equal amounts (30 μg/load) of protein samples were resolved by SDS-PAGE on 10% gels (Bio-Rad Laboratories, Inc.) and transferred to polyvinylidene fluoride difluoride membranes (Merck KGaA). Subsequently, 5% bovine serum albumin (Gibco; Thermo Fisher Scientific, Inc.) was selected to block the membranes for 1 h at room temperature, which were then incubated with primary antibodies against FLNB (ABclonal Biotechnology Co., Ltd.; 1:500, cat. no. A2481), NLR family apoptosis inhibitory protein (NAIP; BIOSS; 1:1,000; cat. no. bs-5804R), mitogen-activated protein kinase kinase 7 (MAP2K7; ABclonal Biotechnology Co., Ltd.; 1:1,000; cat. no. A2186) and GAPDH (ABclonal Biotechnology Co., Ltd.; 1:50,000; cat. no. AC036) at 4°C overnight with gentle rocking. The membranes were then washed three times, and then incubated with a secondary

antibody [peroxidase-conjugated AffiniPure goat Anti-Rabbit IgG (H+L); 1:5,000; cat. no. ZB-2301; Origene Technologies, Inc.] at room temperature for 2 h, and immunoreactivity was detected with ECL substrate (Thermo Fisher Scientific, Inc.). GAPDH was used as an internal control.

**Functional enrichment analysis.** To determine functional categories of DEGs, Gene Ontology (GO; <http://geneontology.org/>) and Kyoto Encyclopedia of Genes and Genomes (KEGG Database 2017/6/5; <https://www.genome.jp/kegg/>) pathways enrichment analysis was performed using the KOBAS 2.0 server (23). The most enriched 10 terms were selected and plotted.

## Results

**FLNB knockdown significantly inhibits apoptosis of HeLa cells.** Previous studies demonstrated that *FLNB* regulates proliferation of chondrocytes (24) and *FLNB* plays a causal role in the regulation of EMT in human breast cancer (11). Therefore, it was hypothesized that *FLNB* might regulate proliferation or apoptosis in cancer cells. A cell model was constructed by knocking down *FLNB* using shRNA in HeLa cells. The expression of *FLNB* was examined in HeLa cells, which were transfected with empty vector or shRNA with three experimental repeats by RT-qPCR. The mRNA level of *FLNB* was decreased in shRNA-transfected cells (Fig. 1A). Cell proliferation was significantly increased by knockdown of *FLNB* (shFLNB; P=0.025; Fig. 1B); however, shFLNB significantly reduced cell apoptosis (P<0.05; Fig. 1C and D). These results suggested that shFLNB significantly inhibited apoptosis in HeLa cells.

**RNA-seq and DEG analysis.** To investigate *FLNB*-mediated transcriptional regulation, cDNA libraries on shFLNB and control cells were constructed for RNA-seq. Utilizing the Illumina HiSeq X Ten platform, two biological replicates were used and yielded a total of 81.7±8.6 M 150 nucleotide paired-end raw reads per sample. After removing adaptors and low-quality reads, around 78.3±8.4 M high-quality reads were generated, 84.15-89.69% of the reads from each sample could be uniquely aligned to the human GRCh38 genome using TopHat2 (Table SII). Uniquely mapped reads were used to estimate the normalized transcription level as FPKM. In total, 23,763 expressed genes were detected from RNA-seq (Table SIII). The effective knockdown of *FLNB* was further confirmed with RNA-seq data (Fig. 2A), which was consistent with the RT-qPCR results (Fig. 1A). FPKM values for all 23,763 genes were used to generate a Pearson's distance correlation matrix to compare the transcriptomes from each sample. The heatmap demonstrated that shFLNB and the control were distinguished, and two biological replicates were highly correlated (Fig. 2B).

The DEGs between the shFLNB and control cells were investigated using the edgeR package (19). In total, 826 upregulated and 363 downregulated DEGs (Table SIV) were identified (log<sub>2</sub> fold change≥1 and FDR <5%). The DEGs associated with shFLNB are presented in a volcano plot (Fig. 2C). The expression heatmap of DEGs indicated that more genes were upregulated upon shFLNB transfection (Fig. 2D). It was




Figure 1. Knockdown of *FLNB* promotes proliferation and inhibits apoptosis of HeLa cells. (A) Relative mRNA expression of *FLNB* in HeLa cells after it was knocked down using *FLNB*-specific shRNA was determined by reverse transcription-qPCR. shFLNB\_1 and shFLNB\_2 indicate two biological repeats of HeLa cells transfected with *FLNB*-specific shRNA. Ctrl\_1 and Ctrl\_2 indicate two biological repeats of HeLa cells transfected with empty vector as controls. (B) Cell proliferation of shFLNB was measured by an MTT assay in HeLa cells. Cell apoptosis of cells transfected with shFLNB was measured by (C) flow cytometry and (D) subsequent analysis by a 7-AAD and Annexin V assay. \* $P < 0.05$  and \*\* $P < 0.01$  vs. respective Ctrl. *FLNB*, filamin B; sh, short hairpin; qPCR, quantitative PCR; Ctrl, control; 7-AAD, 7-amino actinomycin D; OD, optical density; PE, phycoerythrin.

additionally identified that the mRNA expression of *MMP-9* was downregulated after knockdown of *FLNB* in HeLa cells (Table SIII), which is not consistent with that reported in mouse embryonic fibroblasts (9).

DESeq2 (20) was used to detect DEGs, to compare the results with edgeR. A total of 120 upregulated and 12 downregulated DEGs were identified (FDR <5%; Fig. 2E). This suggested that DESeq2 was more stringent than edgeR in recovering DEGs. The Venn diagram demonstrated that 63% of DEGs based on DESeq2 were also identified by edgeR (Fig. 2F). DESeq2 is more inclined to identify DEGs with higher expression compared with edgeR (Fig. 2G).

*Knockdown of FLNB in HeLa cells preferentially regulates transcription level variation of tumorigenesis and cartilage development-related genes.* To further examine the potential biological roles of these DEGs regulated by *FLNB*, GO and KEGG enrichment analysis was performed. The top 10 biological process terms of the GO analysis demonstrated that shFLNB-upregulated genes were strongly enriched in 'membrane depolarization involved in regulation of action

potential', 'transmembrane transport', 'negative regulation of neuron apoptotic process', 'cartilage development' and 'extracellular matrix organization' (Fig. 3A). The downregulated genes were enriched in 'signal transduction', 'cell adhesion', 'angiogenesis', 'inflammatory response', 'innate immune response' and 'cell differentiation' (Fig. 3B). Based on the KEGG analysis (Fig. 3C), the pathways of upregulated gene sets were mainly associated with the 'GABAergic synapse', 'ABC transporters' and 'ECM-receptor interaction' signaling pathway. 'Leukocyte transendothelial migration', 'cell adhesion molecules (CAMs)' and 'transcriptional misregulation in cancer' pathways were significantly enriched in downregulated gene sets (Fig. 3D; Table SV).

*FLNB regulates AS in HeLa cells.* Since RNA-seq technology provides an opportunity to study AS, transcriptome data were used to examine ASEs that might be regulated by *FLNB* in HeLa cells. Spliced reads account for 48.46-53.99% of all uniquely mapped reads obtained from shFLNB and control cells (Table SII). Of the 367,321 annotated exons from the reference genome, 224,199 were detected. Using Tophat2,




Figure 2. RNA-seq and DEG analysis. (A) Comparison of *FLNB* expression levels (FPKM) between shFLNB and control using RNA-seq data. (B) Pearson's correlation analysis of the gene expression between all biological RNA samples. (C) Volcano plot presents DEGs by shFLNB compared with control cells from two samples in each group as experimental replicates. Red indicates upregulated genes ( $\log_2 FC \geq 1$  and  $FDR < 0.05$ ) and blue indicates downregulated genes ( $\log_2 FC \leq -1$  and  $FDR < 0.05$ ). (D) Expression heatmap of all 1,189 significant DEGs between shFLNB and control cells. (E) MA-plot for differential expression analysis using DESeq2. The x-axis indicates the mean of normalized counts and the y-axis indicates the  $\log_2$  fold change. (F) Venn diagram showing the overlapped upregulated (left) and downregulated (right) genes detected by edgeR and DESeq2. (G) Cumulative profiles of genes expression level of DEGs from DESeq2 and edgeR. RNA-seq, RNA-sequencing; DEG, differentially expressed gene; *FLNB*, filamin B; FPKM, fragments per kilobase of transcript per million fragments mapped; sh, short hairpin; FC, fold change; FDR, false discovery rate; Ctrl, control.

151,708 annotated splice junctions and 108,767 novel splice junctions were detected, accounting for 40% of the total. A total of 16,783 known ASEs (defined in the reference genome) and 46,959 new splicing events (not including intron retention) were identified using the previously published ABLas software tool (Table SVI). These results suggested that splicing in human is more complex than previously hypothesized.

For each ASE, the differential splicing patterns usage between shFLNB and control cells was calculated. A total of 402 significant differential ASEs in 363 genes was identified (AS ratio difference  $\geq 0.2$  and P-value  $\leq 0.05$ ; Table SVII). In detail, these ASEs include 48 ES, 49 cassette exon, 75 A5SS, 65 A3SS and 119 intron retention (Fig. 4A). Compared with the control cells, an enrichment of ES and a depletion of cassette exon in shFLNB were observed, suggesting that exon inclusion is suppressed by FLNB silencing (Fig. 4A). To examine the changes in ASEs attributed to transcription regulation, genes with differential expression level and ASEs were overlapped. The present results identified that there were only four DEGs with significantly altered splicing. Notably, metastasis associated lung adenocarcinoma transcript 1 (MALAT1), as

a well-known long non-coding RNA associated with cancer metastasis, demonstrated changes in expression and AS after FLNB knockdown (Fig. 4B).

GO functional clustering analysis demonstrated that the alternative spliced genes were enriched in 'organ morphogenesis', 'apoptotic process', 'cell death' and 'signal transduction' (Fig. 4C). KEGG pathways were most enriched in those involved in 'Adherens junctions', 'GnRH signaling pathway', 'Axon guidance', 'Bacterial invasion of epithelial cells' and 'Mineral absorption' pathways (Fig. 4D; Table SVIII). These results suggested that *FLNB* knockdown markedly regulated AS of apoptosis-related genes and genes involved in skeletal development.

*RT-qPCR validation of DEGs and ASEs by FLNB knockdown in HeLa cells.* A number of important tumorigenesis and skeletal development-related DEGs and ASEs in HeLa cells were further validated by RT-qPCR. A total of nine DEGs, including ATPase copper transporting  $\alpha$  (ATP7A), bone morphogenetic protein 7 (BMP7), collagen type II  $\alpha$  1 chain (COL2A1), matrix metalloproteinase 13 (MMP13),




Figure 3. GO and KEGG analysis of differentially expressed genes between short hairpin *FLNB*-transfected and control HeLa cells. Top 10 most enriched GO terms (biological process) of (A) upregulated and (B) downregulated genes upon *FLNB* knockdown. Rectangles around GO terms indicate notable cancer-related and cartilage development terms. Top 10 most enriched KEGG pathways of (C) upregulated and (D) downregulated genes upon *FLNB* knockdown. GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; *FLNB*, filamin B.




Figure 4. Alternative splicing analysis by shFLNB. (A) Classification of significant changes in alternative splicing after FLNB knockdown. (B) Overlap of DEGs and genes with differential alternative splicing (RASG). Top 10 (C) GO biological process terms and (D) KEGG pathways of genes with differential alternative splicing events between shFLNB and the control. Rectangles around GO terms /KEGG pathways indicate notable apoptotic-related and cartilage development terms. sh, short hairpin; FLNB, filamin B; DEG, differentially expressed genes; GO, Gene Ontology; KEGG, Kyoto Encyclopedia of Genes and Genomes; 3pMXE, mutually exclusive 3'untranslated regions; 5pMXE, mutually exclusive 5'untranslated regions; A3SS, alternative 3'splice site; A5SS, alternative 5'splice site; ES, exon skipping; IntronR, intron retention; RASE, regulated alternative splicing events; RASG, genes with differential alternative splicing; KIF9, kinesin family member 9; SLC25A36, solute carrier family 25 member 36; MALAT1, metastasis associated lung adenocarcinoma transcript 1.

interleukin 23 subunit  $\alpha$  (IL23A), MALAT1, NAIP, solute carrier family 25 member 36 and ghrelin and obestatin prepropeptide (GHRL) were evaluated, although expression of GHRL did not yield sufficient PCR signals. The results of all other eight genes upon *FLNB* silencing matched well with the RNA-seq data, suggesting that *FLNB*-regulated DEGs identified from RNA-seq data are acceptable (Fig. 5A and B). A total of two apoptotic-related proteins were detected by western blotting in the shFLNB and control cells; NAIP (negative regulator of apoptosis) was upregulated and MAP2K7 (positive regulator of apoptosis) was downregulated in the shFLNB cells compared with the control cells (Fig. 5C). A total of four FLNB-regulated splicing events located in vitamin D receptor (VDR), phosphofurin acidic cluster sorting

protein 2 (PACS2), MAP2K7 and MALAT1 were validated by designing PCR primer pairs (Table SI), which amplify both long and short splicing isoforms in the same reaction (Fig. 6). These four ASEs validated by qPCR were in agreement with the RNA-seq results. The ratio of two splicing patterns in each ASE were significantly altered after FLNB-knockdown. These experimental results further suggested that *FLNB* plays an important regulatory role in gene expression and AS in HeLa cell.

### Discussion

The present study is the first study, to the best of the authors' knowledge, to perform entire transcriptome analysis with the




Figure 5. Validation of *FLNB*-regulated genes (DEGs). (A) Relative expression level (FPKM, up) and RT-qPCR measurement (down) of cartilage development-related DEGs. (B) Related expression level (FPKM, up) and RT-qPCR measurement (down) of apoptotic-related DEGs. (C) Western blot analysis of two apoptotic-related proteins in shFLNB and Ctrl HeLa cells. *FLNB*, filamin B; DEGs, differentially expressed genes; FPKM, fragments per kilobase of transcript per million fragments mapped; RT-qPCR, reverse transcription-quantitative PCR; sh, short hairpin; Ctrl, control; ATP7A, ATPase copper transporting  $\alpha$ ; BMP7, bone morphogenetic protein 7; COL2A1, collagen type II  $\alpha$  1 chain; MMP13, matrix metalloproteinase 13; IL23A, interleukin 23 subunit  $\alpha$ ; MALAT1, metastasis associated lung adenocarcinoma transcript 1; NAIP, NLR family apoptosis inhibitory protein; SLC25A36, solute carrier family 25 member 36; MAP2K7, mitogen-activated protein kinase kinase 7.

knockdown of *FLNB* in a cancer cell line (HeLa cells). The widespread effects of inactivation of *FLNB* on multiple biological functions were identified, especially tumorigenesis and skeletal development. After *FLNB* knockdown in HeLa cells, compared with the control, it was identified that the level of apoptosis significantly decreased, consistent with the suppressive role in tumor progression of *FLNB* as reported in mouse embryonic fibroblasts (9). Furthermore, the transcriptome analysis demonstrated that *FLNB* knockdown led to upregulation of genes that

can negatively regulate the apoptotic process, including genes such as *NAIP*, while significantly downregulating inflammatory and immune-related genes. Additionally, *FLNB* knockdown resulted in the deregulation of the AS of hundreds of genes; many were enriched in the top three GO functional terms associated with apoptosis. Notably, it was observed that *FLNB*-regulated the expression of genes in skeletal development-related pathways, such as 'cartilage development' and 'mineral absorption' at both the AS and mRNA levels. These findings together suggested




Figure 6. Validation of *FLNB*-affected ASEs. Genome visualization (left panel) shows *FLNB*-regulated ASEs in sh*FLNB* and control. (A) Validation of an ASE of VDR in HeLa cells. (B) Validation of an ASE of PACS2 in HeLa cells. (C) Validation of an ASE of MAP2K7 in HeLa cells. (D) Validation of an ASE of MALAT1 in HeLa cells. The number of junction reads were marked on the line representing splice junction composing ASE. The structures of ASEs are depicted in the top-right panel. The altered ratio of ASEs in RNA-sequencing and in reverse transcription-quantitative PCR were calculated and plotted (right panel, bottom). *FLNB*, filamin B; ASEs, alternative splicing events; sh/SH, short hairpin; NC, negative control; VDR, vitamin D receptor; PACS2, phosphofurin acidic cluster sorting protein 2; MAP2K7, mitogen-activated protein kinase kinase 7; MALAT1, metastasis associated lung adenocarcinoma transcript 1. \* $P < 0.05$  and \*\*\* $P < 0.001$  vs. respectively NC.

that *FLNB* can extensively regulate pre-mRNA AS in cancer cells, which may be exerted via its RNA binding capability. The *FLNB*-regulated mRNA expression level could be resulted from either *FLNB*-regulated mRNA stability or transcription directly or indirectly. The present data supported a model that *FLNB*-knockdown can inhibit cancer cell apoptosis via regulation of AS and mRNA levels of the apoptotic genes. The present results demonstrated that *FLNB* regulates the AS and mRNA levels of functional related genes, which may provide insight for the current understanding for *FLNB* biology and regulatory mechanisms, as well as for *FLNB*-targeted anti-cancer therapies.

A number of previous studies demonstrated that *FLNB* mutations or deficiencies result in multiple skeletal hypogenesis; the clinical symptoms usually manifest as a reduction of bone mineral density (BMD), ossification of intervertebral disc, disturbance of proliferation, differentiation and apoptosis in chondrocytes, and impairment of angiogenesis (24-26).

The present DEG analysis identified that *FLNB* knockdown increased the expression of genes relevant to cartilage development, including *MMP13*, *COL2A1*, *BMP7* and *ATP7A* in HeLa cells, which need further verification in cartilage cells (27). Additionally, previous studies (28,29) demonstrated that *FLNB* mutations are associated with a reduction in BMD; however, the effect of *FLNB* mutations on bone remodeling is largely unclarified based on functional studies. In the present study, it was observed that knockdown of *FLNB* altered the splicing pattern of *VDR*. *VDR* is a member of the nuclear hormone receptor superfamily, and is a ligand-inducible transcription factor (30). A recent study suggested that alternatively spliced transcript variants encoding different isoforms in *VDR* genes are important in regulating the metabolic processes that affect BMD (31). Indeed, the *VDR* gene FokI and BsmI polymorphisms are significantly associated with low BMD (32). These results provide insight into the molecular mechanism of BMD

caused by *FLNB* dysfunction, and cartilage cells should be used in future studies to verify the regulatory role of *FLNB*.

Recently, *FLNB* has been considered one of the biomarkers for cancer. Splicing variants of *FLNB* expression have been reported to play key roles in the proliferation and differentiation of tumor cells (33). A recent study demonstrated that in HMLE cells (immortalized human mammary epithelial cells), *FLNB* interacts with forkhead box C1 (FOXC1) to form a complex (11). *FLNB* exon skipping leads to a decrease in FLNB protein located in the nucleus, thus the reduced interaction between FLNB, FOXC1 and PBX homeobox 1 leads to the release of FOXC1 to promote EMT (11). Th{Li, 2018 #58} is finding suggested that *FLNB* plays an important regulatory role in tumorigenesis. In the present study, it was demonstrated that *FLNB* also had transcriptional and post-transcriptional regulatory functions in HeLa cells.

DEGs between shFLNB and control HeLa cells were obtained. GO and KEGG enrichment analyses demonstrated that upregulated genes were enriched in the 'negative regulation of the neuron apoptotic process' pathway, and downregulated genes were enriched in 'inflammatory response' and 'innate immune response', which may contribute to the survival of cancer cells. Notably, it was verified that *FLNB* knockdown increased the expression of *NAIP* and *MALAT1*.

*IL23A* associates with interleukin 12B to form interleukin (IL)-23, a heterodimeric cytokine which induces autoimmune inflammation, and is related to tumor incidence and growth (34). Low concentrations of IL-23 promote the proliferation of lung cancer cells, whereas high concentrations of IL-23 inhibit proliferation (35). This is consistent with the fact that FLNB knockdown promotes cell proliferation. *NAIP* is one of eight human inhibitors of apoptosis proteins that have been identified (36). *NAIP* has been suggested to have an important role in protecting cells against apoptosis (37). Although *NAIP* is generally thought to be expressed in nerve cells, *NAIP* is weakly linked to unfavorable prognosis in multiple cancer types, which indicates the precise role of *NAIP* in the dysregulation of apoptosis in cancer (38). The present results suggested that *FLNB* may control the expression of *NAIP*, and thus affect apoptosis of cancer cells. *MALAT1*, a long non-coding RNA, is a transcriptional regulator for numerous genes, including some genes related with cancer metastasis and cell migration, and *MALAT1* is involved in cell cycle regulation (39). Upregulation of *MALAT1* in multiple cancerous tissues was associated with the proliferation and metastasis of tumor cells (39). In conclusion, *FLNB* knockdown results in abnormal expression of many important genes associated with tumorigenesis, demonstrating the important regulatory role of *FLNB* in the process of cancer.

Furthermore, it was identified that AS genes regulated by *FLNB* were significantly enriched in the 'apoptotic process' and 'cell death' pathways. The *FLNB*-regulated AS genes in these pathways included *PACS2*, *MALAT1* and *MAP2K7*, which were validated by RT-qPCR. In particular, *PACS2* has been shown to be a multi-functional sorting protein, which regulates endoplasmic reticulum-mitochondria communication and Bid-mediated apoptosis (40). *PACS2* also mediates tumor necrosis factor-related apoptosis-inducing ligand lysosomes, interacting with Bim and Bax to permeabilize lysosomes and induce apoptosis (41). The present findings regarding

*FLNB*-mediated AS of apoptotic-regulating genes suggested a more complex network among the apoptotic regulation process in cancer, which supports a previous study demonstrating that *FLNB* knockdown in mouse embryonic fibroblasts leads to increased proteolytic activity of *MMP-9* (9). In the present study, it was identified that the mRNA expression of *MMP-9* was downregulated after knockdown of FLNB in HeLa cells. Further research is required to determine whether or not *FLNB* regulates transcription and AS by binding to RNA as an RBP.

### Acknowledgements

The authors would like to thank Dr Yi Zhang (ABLife BioBigData Institute) for her helpful discussions.

### Funding

The present study was supported by The National Natural Science Foundation of China (grant no. 81860746) and The Joint Fund of the National Natural Science Foundation of China (grant no. U1503221).

### Availability of data and materials

RNA-sequencing data in the present study have been deposited in NCBI's Gene Expression Omnibus and are accessible through GEO (<https://www.ncbi.nlm.nih.gov/geo>) series (accession no. GSE134769).

### Authors' contributions

HRM and LC contributed to the study design. FW, CC, RJ, HKZ, SW and ZQ conducted the experiments and/or performed data analysis. HRM and CC prepared the manuscript. ZX made the part analysis of bioinformation data. All authors read and approved the final manuscript.

### Ethics approval and consent to participate

Not applicable.

### Patient consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### References

1. Takafuta T, Wu G, Murphy GF and Shapiro SS: Human beta-filamin is a new protein that interacts with the cytoplasmic tail of glycoprotein Ibalpha. *J Biol Chem* 273: 17531-17538, 1998.
2. Brocker F, Bardenheuer W, Vieten L, Jülicher K, Werner N, Marquitan G, Michael D, Opalka B and Schütte J: Assignment of human filamin gene FLNB to human chromosome band 3p14.3 and identification of YACs containing the complete FLNB transcribed region. *Cytogenet Cell Genet* 85: 267-268, 1999.
3. Stossel TP, Condeelis J, Cooley L, Hartwig JH, Noegel A, Schleicher M and Shapiro SS: Filamins as integrators of cell mechanics and signalling. *Nat Rev Mol Cell Biol* 2: 138-145, 2001.

4. Feng Y and Walsh CA: The many faces of filamin: A versatile molecular scaffold for cell motility and signalling. *Nat Cell Biol* 6: 1034-1038, 2004.
5. Gorlin JB, Yamin R, Egan S, Stewart M, Stossel TP, Kwiatkowski DJ and Hartwig JH: Human endothelial actin-binding protein (ABP-280, nonmuscle filamin): A molecular leaf spring. *J Cell Biol* 111: 1089-1105, 1990.
6. Baldassarre M, Razinia Z, Burande CF, Lamsoul I, Lutz PG and Calderwood DA: Filamins regulate cell spreading and initiation of cell migration. *PLoS One* 4: e7830, 2009.
7. Yang CF, Wang CH, Siong H'ng W, Chang CP, Lin WD, Chen YT, Wu JY and Tsai FJ: Filamin B loss-of-function mutation in dimerization domain causes autosomal-recessive spondylocarpotarsal synostosis syndrome with Rib anomalies. *Hum Mutat* 38: 540-547, 2017.
8. Bicknell LS, Morgan T, Bonafe L, Wessels MW, Bialer MG, Willems PJ, Cohn DH, Krakow D and Robertson SP: Mutations in FLNB cause boomerang dysplasia. *J Med Genet* 42: e43, 2005.
9. Bandaru S, Zhou AX, Rouhi P, Zhang Y, Bergo MO, Cao Y and Akyurek LM: Targeting filamin B induces tumor growth and metastasis via enhanced activity of matrix metalloproteinase-9 and secretion of VEGF-A. *Oncogenesis* 3: e119, 2014.
10. Iguchi Y, Ishihara S, Uchida Y, Tajima K, Mizutani T, Kawabata K and Haga H: Filamin B Enhances the invasiveness of cancer cells into 3D collagen matrices. *Cell Struct Funct* 40: 61-67, 2015.
11. Li J, Choi PS, Chaffer CL, Labella K, Hwang JH, Giacomelli AO, Kim JW, Ilic N, Doench JG, Ly SH, *et al*: An alternative splicing switch in FLNB promotes the mesenchymal cell state in human breast cancer. *Elife* 7: e37184, 2018.
12. Baltz AG, Munschauer M, Schwanhauser B, Vasile A, Murakawa Y, Schueler M, Youngs N, Penfold-Brown D, Drew K, Milek M, *et al*: The mRNA-bound proteome and its global occupancy profile on protein-coding transcripts. *Mol Cell* 46: 674-690, 2012.
13. Kafasla P, Skliris A and Kontoyiannis DL: Post-transcriptional coordination of immunological responses by RNA-binding proteins. *Nat Immunol* 15: 492-502, 2014.
14. Zhou H, Mangelsdorf M, Liu J, Zhu L and Wu JY: RNA-binding proteins in neurological diseases. *Sci China Life Sci* 57: 432-444, 2014.
15. Wurth L and Gebauer F: RNA-binding proteins, multifaceted translational regulators in cancer. *Biochim Biophys Acta* 1849: 881-886, 2015.
16. Livak KJ and Schmittgen TD: Analysis of relative gene expression data using real-time quantitative PCR and the 2<sup>-</sup>(Delta Delta C(T)) method. *Methods* 25: 402-408, 2001.
17. Kim D, Pertea G, Trapnell C, Pimentel H, Kelley R and Salzberg SL: TopHat2: Accurate alignment of transcriptomes in the presence of insertions, deletions and gene fusions. *Genome Biol* 14: R36, 2013.
18. Trapnell C, Williams BA, Pertea G, Mortazavi A, Kwan G, van Baren MJ, Salzberg SL, Wold BJ and Pachter L: Transcript assembly and quantification by RNA-Seq reveals unannotated transcripts and isoform switching during cell differentiation. *Nat Biotechnol* 28: 511-515, 2010.
19. Robinson MD, McCarthy DJ and Smyth GK: EdgeR: A Bioconductor package for differential expression analysis of digital gene expression data. *Bioinformatics* 26: 139-140, 2010.
20. Love MI, Huber W and Anders S: Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2. *Genome Biol* 15: 550, 2014.
21. Xia H, Chen D, Wu Q, Wu G, Zhou Y, Zhang Y and Zhang L: CELF1 preferentially binds to exon-intron boundary and regulates alternative splicing in HeLa cells. *Biochim Biophys Acta Gene Regul Mech* 1860: 911-921, 2017.
22. Jin L, Li G, Yu D, Huang W, Cheng C, Liao S, Wu Q and Zhang Y: Transcriptome analysis reveals the complexity of alternative splicing regulation in the fungus *Verticillium dahliae*. *BMC Genomics* 18: 130, 2017.
23. Xie C, Mao X, Huang J, Ding Y, Wu J, Dong S, Kong L, Gao G, Li CY and Wei L: KOBAS 2.0: A web server for annotation and identification of enriched pathways and diseases. *Nucleic Acids Res* 39 (Web Server Issue): W316-W322, 2011.
24. Hu J, Lu J, Lian G, Ferland RJ, Dettenhofer M and Sheen VL: Formin 1 and Filamin B physically interact to coordinate chondrocyte proliferation and differentiation in the growth plate. *Hum Mol Genet* 23: 4663-4673, 2014.
25. Wilson SG, Jones MR, Mullin BH, Dick IM, Richards JB, Pastinen TM, Grundberg E, Ljunggren O, Surdulescu GL, Dudbridge F, *et al*: Common sequence variation in FLNB regulates bone structure in women in the general population and FLNB mRNA expression in osteoblasts in vitro. *J Bone Miner Res* 24: 1989-1997, 2009.
26. Zieba J, Forlenza KN, Khatra JS, Sarukhanov A, Duran I, Rigueur D, Lyons KM, Cohn DH, Merrill AE and Krakow D: TGFβ and BMP dependent cell fate changes due to loss of filamin B produces disc degeneration and progressive vertebral fusions. *PLoS Genet* 12: e1005936, 2016.
27. Lu J, Lian G, Lenkinski R, De Grand A, Vaid RR, Bryce T, Stasenko M, Boskey A, Walsh C and Sheen V: Filamin B mutations cause chondrocyte defects in skeletal development. *Hum Mol Genet* 16: 1661-1675, 2007.
28. Mullin BH, Mamotte C, Prince RL, Spector TD, Dudbridge F and Wilson SG: Conditional testing of multiple variants associated with bone mineral density in the FLNB gene region suggests that they represent a single association signal. *BMC Genet* 14: 107, 2013.
29. Xu Q, Wu N, Cui L, Wu Z and Qiu G: Filamin B: The next hotspot in skeletal research? *J Genet Genomics* 44: 335-342, 2017.
30. Campbell MJ and Adorini L: The vitamin D receptor as a therapeutic target. *Expert Opin Ther Targets* 10: 735-748, 2006.
31. Nakamichi Y, Udagawa N, Suda T and Takahashi N: Mechanisms involved in bone resorption regulated by vitamin D. *J Steroid Biochem Mol Biol* 177: 70-76, 2018.
32. Bao L, Chen M, Lei Y, Zhou Z, Shen H and Le F: Association between vitamin D receptor Bsm1 polymorphism and bone mineral density in pediatric patients: A meta-analysis and systematic review of observational studies. *Medicine (Baltimore)* 96: e6718, 2017.
33. Tsui JC, Lau CP, Cheung AC, Wong KC, Huang L, Tsui SK and Kumta SM: Differential expression of filamin B splice variants in giant cell tumor cells. *Oncol Rep* 36: 3181-3187, 2016.
34. Langowski JL, Zhang X, Wu L, Mattson JD, Chen T, Smith K, Basham B, McClanahan T, Kastelein RA and Oft M: IL-23 promotes tumour incidence and growth. *Nature* 442: 461-465, 2006.
35. Li J, Zhang L, Zhang J, Wei Y, Li K, Huang L, Zhang S, Gao B, Wang X and Lin P: Interleukin 23 regulates proliferation of lung cancer cells in a concentration-dependent way in association with the interleukin-23 receptor. *Carcinogenesis* 34: 658-666, 2013.
36. Davoodi J, Ghahremani MH, Es-Haghi A, Mohammad-Gholi A and Mackenzie A: Neuronal apoptosis inhibitory protein, NAIP, is an inhibitor of procaspase-9. *Int J Biochem Cell Biol* 42: 958-964, 2010.
37. Chamaillard M, Girardin SE, Viala J and Philpott DJ: Nods, Nalps and Naip: Intracellular regulators of bacterial-induced inflammation. *Cell Microbiol* 5: 581-592, 2003.
38. Finlay D, Teriete P, Vamos M, Cosford NDP and Vuori K: Inducing death in tumor cells: Roles of the inhibitor of apoptosis proteins. *F1000Res* 6: 587, 2017.
39. Li ZX, Zhu QN, Zhang HB, Hu Y, Wang G and Zhu YS: MALAT1: A potential biomarker in cancer. *Cancer Manag Res* 10: 6757-6768, 2018.
40. Myhill N, Lynes EM, Nanji JA, Blagoveshchenskaya AD, Fei H, Carmine Simmen K, Cooper TJ, Thomas G and Simmen T: The subcellular distribution of calnexin is mediated by PACS-2. *Mol Biol Cell* 19: 2777-2788, 2008.
41. Werneburg NW, Bronk SF, Guicciardi ME, Thomas L, Dikeakos JD, Thomas G and Gores GJ: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) protein-induced lysosomal translocation of proapoptotic effectors is mediated by phosphofurin acidic cluster sorting protein-2 (PACS-2). *J Biol Chem* 287: 24427-24437, 2012.

